Bioliberty Secures $10.2 Million, Revolutionizing Post-Acute Care
March 25, 2026, 3:36 am
Bioliberty, a leading healthtech firm, announced a $10.2 million funding round. This accelerates its AI and robotics-driven Lifehub platform. The technology revolutionizes physical and occupational therapy. It focuses on post-acute care settings. Lifehub offers objective functional mobility data. It enhances patient recovery. It improves discharge planning. The funding supports U.S. commercialization. It also expands capabilities to patients' homes with Lifehub Home. New board members bring key industry expertise. The company’s innovative approach reduces readmissions. It optimizes care decisions. This investment signals strong market confidence in Bioliberty’s mission. It leverages advanced computer vision and AI for predictive patient insights. This transformative platform aims for widespread adoption. It ensures better outcomes across rehabilitation networks. Bioliberty holds multiple patents. Its products are FDA-registered.
Bioliberty is transforming post-acute care. The healthtech innovator recently secured $10.2 million in new financing. This substantial investment propels its functional intelligence platform. The focus remains on physical and occupational therapy delivery. The funds directly support U.S. commercialization efforts. They also advance the Lifehub platform.
This financing includes an $8.2 million Series A round. The Scottish National Investment Bank led a significant $4 million portion. Additional investors participated. These included Archangels, Eos Advisory, Old College Capital, and Hanna Capital SEZC. New investor Conduit Connect also joined. This Series A follows a prior $2 million pre-Series A round. That funding concluded in mid-2025. Bioliberty has now raised a total of $17.5 million. This has occurred since its founding in 2023.
The Lifehub platform is central to Bioliberty's mission. It launched its Lifehub Clinic platform in 2025. This system leverages artificial intelligence and robotics. It objectively monitors functional recovery. It significantly enhances therapy delivery. Its primary application is in post-acute care environments. The company reports growing adoption across major U.S. rehabilitation providers. Partnerships exist with one of the largest rehabilitation networks. Sheltering Arms Institute also utilizes the technology. Further collaborations include Mount Sinai and the U.S. Department of Veterans Affairs. These partnerships underscore the platform’s real-world utility.
Bioliberty addresses a critical gap in modern healthcare. The system provides objective functional mobility data. This data is vital in today's value-based care models. Accurate measurement of patient function holds immense importance. It helps reduce hospital readmissions. It also significantly improves discharge planning processes. Bioliberty’s technology empowers clinicians. They can precisely track patient recovery. They can identify high-risk patients proactively. This enables data-driven care decisions. The approach standardizes care across expanding networks.
The company's product line extends beyond the clinic. Lifehub Home represents a key expansion. This system extends therapy and monitoring directly into patients' homes. It ensures continuity of care. It provides ongoing functional insights. This in-home capability broadens access to advanced therapy. It supports patient progress outside traditional settings. The platform integrates expanded computer vision capabilities. AI-driven assessments build predictive product functionality. These insights help anticipate patient pathways. They contribute to reducing the overall cost of care.
Innovation also includes the Lifeglov. This soft robotic glove offers rehabilitation for hand strength. It assists with both closing and opening movements. The Lifeglov monitors key metrics for upper limb mobility. It tracks patient improvement throughout their rehabilitation journey. Both Lifehub and Lifeglov are FDA-registered. Bioliberty holds multiple patents across its core technologies. This solidifies its position as a leader in rehabilitative technology.
The financing round also strengthened Bioliberty's leadership. Two prominent figures joined the Board of Directors. Russell Bailey now serves on the board. He is President of Lifepoint Rehabilitation. Dana Prommel Strauss also joined. She is Lead Director of Public Policy and Government Affairs at CVS Health. Both bring extensive expertise. Their experience spans post-acute care and healthcare policy. Their insights will guide Bioliberty's strategic direction. This move underscores a commitment to industry integration. It emphasizes navigating complex healthcare landscapes.
Bioliberty’s technology enhances physical and occupational therapists' work. It frees up their hands-on time with patients. Simultaneously, it captures vital functional mobility data. This data has been a "missing link" in therapy. It is crucial for improving discharge planning. It effectively reduces readmissions. These insights are what the post-acute space has sought. The company's platforms offer real, measurable value for providers. They ultimately ensure excellent quality outcomes for patients.
The future for Bioliberty looks promising. The investment fuels continued development. It drives the U.S. commercialization of its advanced systems. The company seeks to scale its impact. It aims to deliver exceptional value. Its transformative solutions are poised for widespread adoption. Bioliberty, based in Edinburgh, Scotland, and Boston, MA, leads this technological shift. It pushes the boundaries of rehabilitative care. The firm builds on initial successes in the U.S. market. It supports providers in improving patient outcomes. Intelligent therapy delivery is its hallmark. Discharge planning now incorporates robust functional data. Bioliberty is shaping the future of recovery. It offers a path to smarter, more effective rehabilitation.
Bioliberty is transforming post-acute care. The healthtech innovator recently secured $10.2 million in new financing. This substantial investment propels its functional intelligence platform. The focus remains on physical and occupational therapy delivery. The funds directly support U.S. commercialization efforts. They also advance the Lifehub platform.
This financing includes an $8.2 million Series A round. The Scottish National Investment Bank led a significant $4 million portion. Additional investors participated. These included Archangels, Eos Advisory, Old College Capital, and Hanna Capital SEZC. New investor Conduit Connect also joined. This Series A follows a prior $2 million pre-Series A round. That funding concluded in mid-2025. Bioliberty has now raised a total of $17.5 million. This has occurred since its founding in 2023.
The Lifehub platform is central to Bioliberty's mission. It launched its Lifehub Clinic platform in 2025. This system leverages artificial intelligence and robotics. It objectively monitors functional recovery. It significantly enhances therapy delivery. Its primary application is in post-acute care environments. The company reports growing adoption across major U.S. rehabilitation providers. Partnerships exist with one of the largest rehabilitation networks. Sheltering Arms Institute also utilizes the technology. Further collaborations include Mount Sinai and the U.S. Department of Veterans Affairs. These partnerships underscore the platform’s real-world utility.
Bioliberty addresses a critical gap in modern healthcare. The system provides objective functional mobility data. This data is vital in today's value-based care models. Accurate measurement of patient function holds immense importance. It helps reduce hospital readmissions. It also significantly improves discharge planning processes. Bioliberty’s technology empowers clinicians. They can precisely track patient recovery. They can identify high-risk patients proactively. This enables data-driven care decisions. The approach standardizes care across expanding networks.
The company's product line extends beyond the clinic. Lifehub Home represents a key expansion. This system extends therapy and monitoring directly into patients' homes. It ensures continuity of care. It provides ongoing functional insights. This in-home capability broadens access to advanced therapy. It supports patient progress outside traditional settings. The platform integrates expanded computer vision capabilities. AI-driven assessments build predictive product functionality. These insights help anticipate patient pathways. They contribute to reducing the overall cost of care.
Innovation also includes the Lifeglov. This soft robotic glove offers rehabilitation for hand strength. It assists with both closing and opening movements. The Lifeglov monitors key metrics for upper limb mobility. It tracks patient improvement throughout their rehabilitation journey. Both Lifehub and Lifeglov are FDA-registered. Bioliberty holds multiple patents across its core technologies. This solidifies its position as a leader in rehabilitative technology.
The financing round also strengthened Bioliberty's leadership. Two prominent figures joined the Board of Directors. Russell Bailey now serves on the board. He is President of Lifepoint Rehabilitation. Dana Prommel Strauss also joined. She is Lead Director of Public Policy and Government Affairs at CVS Health. Both bring extensive expertise. Their experience spans post-acute care and healthcare policy. Their insights will guide Bioliberty's strategic direction. This move underscores a commitment to industry integration. It emphasizes navigating complex healthcare landscapes.
Bioliberty’s technology enhances physical and occupational therapists' work. It frees up their hands-on time with patients. Simultaneously, it captures vital functional mobility data. This data has been a "missing link" in therapy. It is crucial for improving discharge planning. It effectively reduces readmissions. These insights are what the post-acute space has sought. The company's platforms offer real, measurable value for providers. They ultimately ensure excellent quality outcomes for patients.
The future for Bioliberty looks promising. The investment fuels continued development. It drives the U.S. commercialization of its advanced systems. The company seeks to scale its impact. It aims to deliver exceptional value. Its transformative solutions are poised for widespread adoption. Bioliberty, based in Edinburgh, Scotland, and Boston, MA, leads this technological shift. It pushes the boundaries of rehabilitative care. The firm builds on initial successes in the U.S. market. It supports providers in improving patient outcomes. Intelligent therapy delivery is its hallmark. Discharge planning now incorporates robust functional data. Bioliberty is shaping the future of recovery. It offers a path to smarter, more effective rehabilitation.